As cell-based therapies grow more complex and manufacturing networks expand, resilience can’t be an afterthought, and cryopreservation can no longer just be a step that gets validated during development and left alone. It needs to play an ongoing role in product consistency, potency, and reliability.
The post Frozen Does Not Mean Stable: Rethinking Cryopreservation in Cell and Gene Therapy Manufacturing appeared first on MedCity News.
